Finacea’s generics by Glenmark is an infringe on Bayer AG’s Patent, US court
A US court has recently ruled the decision of proposal of the generic version of Finacea, a skin gel, as an act of infringement by Glenmark Pharmaceuticals. The proposed generic version is currently patented by Bayer AG, a gel for treating the common skin condition rosacea.
The federal court in Wilmington, Delaware is reported to have stressed on the fact that Glenmark's proposed gel would be absorbed into the skin in a similar way to Finacea, violating Bayer's patent.
Germany's Bayer had sued Glenmark in 2013 after Glenmark filed an application to market a copycat version of the $95 million drug in the United States
The federal court in Wilmington, Delaware is reported to have stressed on the fact that Glenmark's proposed gel would be absorbed into the skin in a similar way to Finacea, violating Bayer's patent.
Germany's Bayer had sued Glenmark in 2013 after Glenmark filed an application to market a copycat version of the $95 million drug in the United States
Next Story
